Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.22.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2022
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2021

4,512,701

$

3.35

Granted

968,500

2.53

Forfeited

(50,000)

2.53

Vested

(1,984,610)

3.67

Non-vested at March 31, 2022

3,446,591

$

2.95

Summary of stock option award activity

The following table summarizes stock option award activity for the three months ended March 31, 2022:

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2021

270,000

$

3.14

7.44

Granted

Outstanding as of March 31, 2022

270,000

$

3.14

7.19

Vested and exercisable as of March 31, 2022

135,000

$

2.32

7.53

Summary of stock options assumptions used

For the Three Months Ended March 31,

 

    

2022

    

2021

 

Risk-free interest rate

 

%

1.04

%

Expected dividend yield

 

Expected term in years

 

10.0

Expected volatility

 

%

102.71

%

Summary of warrant activities

A summary of warrant activities for the three months ended March 31, 2022 is presented below:

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2021

12,493

$

0.00

3.83

Exercised

Outstanding as of March 31, 2022

12,493

$

0.00

3.58

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three months ended March 31, 2022 and 2021 ($ in thousands):

For the three months ended March 31, 

    

2022

    

2021

Research and development

$

247

$

161

General and administrative

 

528

 

613

Total stock-based compensation expense

$

775

$

774